Premium
Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade
Author(s) -
Yu Shuangjiang,
Wang Chao,
Yu Jicheng,
Wang Jinqiang,
Lu Yue,
Zhang Yuqi,
Zhang Xudong,
Hu Quanyin,
Sun Wujin,
He Chaoliang,
Chen Xuesi,
Gu Zhen
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201801527
Subject(s) - tumor microenvironment , blockade , immune checkpoint , immunotherapy , immune system , cancer research , melanoma , reactive oxygen species , cancer immunotherapy , in vivo , pharmacology , materials science , immunology , medicine , receptor , microbiology and biotechnology , biology
Although cancer immunotherapy based on immune checkpoint inhibitors holds great promise toward many types of cancers, several challenges still remain, associated with low objective response of patient rate as well as systemic side effects. Here, a combination immunotherapy strategy is developed based on a thermogelling reactive oxygen species (ROS)‐responsive polypeptide gel for sustained release of anti‐programmed cell death‐ligand 1 antibody and dextro‐1‐methyl tryptophan, inhibitor of indoleamine‐2,3‐dioxygenase with leveraging the ROS level in the tumor microenvironment. This bioresponsive gel depot can effectively reduce the local ROS level and facilitate release of immunotherapeutics, which leads to enhanced anti‐melanoma efficacy in vivo.